Market research
12V.F Veracyte, Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 33.34
- Analyst target
- 63.17
- Dividend yield
- Not available
- Beta
- 1.95
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 3B
- P/E ratio
- 33.34
- Analyst target
- 63.17
- Dividend yield
- Not available
- Beta
- 1.95
About
About Veracyte, Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Research context
Veracyte, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 12V.F discussion.
5 years, 6 months ago
Veracyte, Inc is currently in a long term downtrend where the price is trading 61.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.3.
Veracyte, Inc's total revenue rose by 16.2% to $35M since the same quarter in the previous year.
Its net income has dropped by 7.9% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.0% to $1M since the same quarter in the previous year.
Based on the above factors, Veracyte, Inc gets an overall score of 3/5.